Simplex Trading
AIMT

Simplex Trading’s Aimmune Therapeutics AIMT Stock Holding History

Simplex Trading’s Portfolio AIMT Stock Details AIMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-142
Closed -$204K – 8752
2020
Q1 		$204K Buy
142
+76
+115% +$1.94K ﹤0.01% 3575
2019
Q4 		$220K Sell
66
-299
-82% -$8.36K ﹤0.01% 3654
2019
Q3 		$764K Buy
365
+329
+914% +$6.72K ﹤0.01% 2209
2019
Q2 		$74K Buy
36
+2
+6% +$41 ﹤0.01% 4492
2019
Q1 		$75K Buy
34
+15
+79% +$353 ﹤0.01% 4642
2018
Q4 		$45K Sell
19
-23
-55% -$595 ﹤0.01% 4630
2018
Q3 		$114K Sell
42
-22
-34% -$622 ﹤0.01% 4309
2018
Q2 		$172K Sell
64
-74
-54% -$2.27K ﹤0.01% 3669
2018
Q1 		$44K Buy
138
+127
+1,155% +$4.47K ﹤0.01% 2570
2017
Q4 		$9K Sell
11
-6
-35% -$194 ﹤0.01% 4042
2017
Q3 		$1K Buy
+17
New +$366 ﹤0.01% 5675
2016
Q4 		– Sell
-30
Closed -$3K – 6833
2016
Q3 		$3K Buy
+30
New +$405 ﹤0.01% 4792

Other funds holding AIMT

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
Fiera Capital (Canada)
Fiera Capital (Canada) Montreal, Quebec, Canada $29.2B AUM 20.16% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

Simplex Trading's AIMT Position: Q2 2020 in Review

Simplex Trading sold out of Aimmune Therapeutics (AIMT) in Q2 2020, closing a stake of 200 shares — an estimated $3.4K sold.

Simplex Trading first reported a position in AIMT in Q3 2016 and held it in 9 quarters. The position peaked at $1.06M in Q4 2019. 165 funds tracked by Wall St. Rank hold AIMT as of Q2 2020.

  • Simplex Trading reported no remaining Aimmune Therapeutics position as of Q2 2020 after selling out during the quarter.
  • Simplex Trading sold 200 Aimmune Therapeutics shares in Q2 2020, an estimated $3.4K.
  • Simplex Trading first reported a position in Aimmune Therapeutics in Q3 2016 and held it in 9 quarters.
  • Simplex Trading's Aimmune Therapeutics position peaked at $1.06M in Q4 2019.
  • 165 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q2 2020.

Based on Simplex Trading's 13F filing for Q2 2020, filed 13 Jul 2020.